PROCYON CORP: management transactions · United States · SEC (Form 4)

About PROCYON CORP

PROCYON CORP (ticker: PCYN) is a U.S.-based company whose securities are not shown in the latest SEC materials as listed on NYSE or NASDAQ; instead, the company appears to trade in the over-the-counter market. In its most recent SEC filings, Procyon is incorporated in Colorado and its principal operating office is in Oldsmar, Florida. The company’s business is largely conducted through its subsidiary AMERX Health Care, which develops and markets proprietary medical products used in the treatment of pressure ulcers, chronic wounds, dermatitis, inflammation, and other skin conditions. Procyon was incorporated in 1987 and materially reshaped its operating model in 1996 with the acquisition of Amerx, establishing a focused wound-care and skin-care platform. From a business-line perspective, Procyon remains a specialized healthcare company rather than a broad diversified medtech group. Its commercial portfolio centers on AMERIGEL, HELIX3 bioactive collagen products, AMERX dressings and wound-care kits, and the EXTREMIT-EASE compression garment line for edema and lymphedema-related applications. Over time, the company has broadened its offering with products such as collagen gels, surgical collagen powder, gauze wound-care kits, foam and hydrocolloid dressings, and related secondary dressing and hygiene items. The strategy is clear: widen the addressable wound-care market while preserving a defensible niche built around branded, proprietary formulations. Competitively, PCYN is best described as a small specialist rather than a scale leader. Its value proposition is based on differentiated product performance, brand recognition within clinician-led channels, and regulatory/commercial features such as FDA registration and Medicare reimbursement coding for selected product lines. The company emphasizes trademarks, proprietary formulations, and in some cases patent protection, which can help support pricing and market access in a category where reimbursement, clinician trust, and repeat usage matter. Distribution is handled through institutional and retail channels, including physicians, nursing homes, home health agencies, pharmacies, independent medical supply stores, and regional or national retail chains. Direct-to-consumer and direct sales websites also support the business. Geographically, the company is still predominantly U.S.-focused, with the vast majority of sales generated domestically. Management also references international distribution inquiries and continued efforts to expand into new geographies, but the commercial footprint remains primarily American. Recent filings indicate that fiscal 2024 sales rose versus fiscal 2023, helped by new market expansion and product-line growth. For investors, PCYN is a micro-cap healthcare story built around steady product-line extension, modest but incremental top-line growth, and the potential to leverage reimbursement status and distributor relationships. In short, Procyon Corp is a niche wound-care and skin-health platform in the United States, traded outside NYSE/NASDAQ, with a business model oriented toward specialized medical products and gradual commercialization rather than scale-driven expansion.